34 results about "Factor XII" patented technology

The present invention relates to methods of introducing one or more cysteine residues into a polypeptide which permit the stabilization of the polypeptide by formation of at least one bond, preferably a disulfide bond, between different domains of the polypeptide. The invention also relates to polypeptides containing such introduced cysteine residue(s), nucleic acids encoding such polypeptides and pharmaceutical compositions comprising such polypeptides or nucleic acids. The invention also relates to vectors, viral particles and host cells containing such nucleic acids, and methods of using them to produce the polypeptides of the invention. Exemplified polypeptides include plasma proteins, including hepatocyte growth factor activator and plasma hyaluronin binding protein, as well as blood coagulation factors, such as Factor VIII, Factor V, Factor XII and prothrombin.

The invention relates to evaluation, assays and treatment of PKAL-mediated disorders. The invention provides assay methods of detecting plasma protease CI inhibitor (Cl-INH) that binds plasma kallikrein, factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment.

This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding the human C1 esterase inhibitor or Factor XII. The invention is also directed to a composition comprising the vector and a method of using the vector to treat or prevent hereditary angioedema.

The invention relates to compounds of formula (I) and methods of treatment by using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. Thecompounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.

The invention relates to polynucleotide agents targeting Factor XII (F12) gene, and methods of using such polynucleotide agents to inhibit expression of Factor XII and to treat subjects having a Factor XII-associated disease, e.g., heredity angioedema (HAE), prekallikrein deficiency, malignant essential hypertension, hypertension, end stage renal disease, or Fletcher Factor Deficiency.

The present invention provides assays for the detection of plasma protease C1 inhibitors (C1-INH) that bind plasma kallikrein, factor XII, or both, and their use to identify enzymes that are pKal-mediated or bradykinin-mediated. Risk of a disorder or use in a subject with a pKal-mediated or bradykinin-mediated disorder. The provided methods allow analysis of patients with plasma kallikrein-mediated angioedema (KMA) or other diseases mediated by pKal that can be used for evaluation and treatment.

RNA interference (RNAi) elicitors for inhibiting Factor XII (F12) gene expression by the RNA interference mechanism are disclosed. Also disclosed are pharmaceutical compositions comprising one or more F12 RNAi elicitors and one or more excipients capable of delivering the RNAi elicitors to hepatocytes. In vivo delivery of F12 RNAi triggers to hepatocytes provides inhibition of F12 gene expression and treatment of angioedema, including hereditary angioedema (HAE), venous thromboembolism (VTE), and angioedema-related diseases.

This invention relates to compounds of formula (I). The compounds of formula (I) are modulators of Factor XII, specifically Factor XIIa. The compounds are inhibitors of Factor XIIa and may be useful as anticoagulants. The compounds of formula (I) may be used in methods of treatment (or prevention) of blood disorders related to bleeding or coagulation.

The invention relates to an inhibitor of Factor XII (FXII) for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia / reperfusion injury in native or transplant kidneys and / or acute kidney injury, a kit for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia / reperfusion injury in native or transplant kidneys, acute kidney injury, renal fibrosis as a result of rejection of a kidney transplant / allograft, and / or fibrosis of a kidney transplant / allograft as a result of rejection or recurrent underlying disease comprising one inhibitor of Factor XII, and an anti-Factor XII (FXII) antibody or antigen binding fragment thereof for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia / reperfusion injury in native or transplant kidneys and / or acute kidney injury comprising one inhibitor of Factor XII.